Search
You're invited to try out the new version of Value Research Online. Click here to begin: https://beta.valueresearchonline.com
Advice
Ask Value Research
Big Questions
Tax Q&A
The Plan
Columns
Econology
First Page
Generally Speaking
Guest Column
Mainstreet
Not Just Kidding
Of This & That...
Straight Talk
Taking Stock
The Chartist
Top of Mind
World Savings Day
Year of SIP
Fund Research
Category Watch
Fund Analysis
House Voice
IPO Analysis
Rating Radar
Stock Research
Data for Thought
Stock Advisor
Stock Analyst Choice
Stock Ideas
Stock Strategy
News & Commentary
Fund News
Fundwire
Marketwire
Newswire
Stockwire
Others
Advertorial
Book Review
Budget Special
First things...
Fund Focus
Fund Manager's View
Fundwise
How I did it
In Remembrance
Income Tax Know How
Insurance
Interview
Learning
Moneywise
Mutual Fund Sahi Hai
Omaha Live
SIP Sahi Hai
Special Report
Tax Saving Alternatives
Using Value Research Online
Vital Statistics
Words Worth

News & Views - Dr. Reddy's Laboratories

Following the recent correction, we went on a search for quality large-cap stocks |
The pharma sector, which once used to be the star of the Street, has been witnessing bad times |
Belonging to the market index is no guarantee that a stock will continue to beat the market and remain an outperformer |
This comparison pits told old rivals against each other using MSCI India Indices. Time determines the answer |
Dr Reddy's says it is very close to completing remediation work at three facilities under the scanner of the USFDA before it approaches the agency for re-inspection |
An analysis of stock market transactions reveals that FIIs and domestic institutions are taking contrasting views on sectors |
Its generics business, which contributes 79% of sales, barely budged from a year ago, and fell 8.3% sequentially |
The ongoing market downturn has put several companies at a bargain. Here are the top Sensex companies that are quoting at a discount |
Even though the USFDA created problems for large pharma companies, their smaller counterparts have been doing very well |
With high numbers of ANDAs, mid-rung pharma companies could outperform their larger peers in the future |
Dr Reddy's Laboratories has proved to be one of the best pharma stocks as far as the growth in its revenues and profitability is concerned |
Each of these companies has faced tough periods but each has overcome them. See what the future holds for these multibaggers |
Home | My Portfolio | ELSS | Funds | Investors' Hangout | Income | Insurance | Value Investing | Learn | Archive | Ask | We're Hiring | Subscribe | About Us | Log In | Free Sign Up